FDA OK of Vivos sleep apnea devices boosts firm’s business

The Vivos OSA device. Image courtesy of Vivos Therapeutics.
The Vivos OSA device. Image courtesy of Vivos Therapeutics.

Vivos Therapeutics announced that orders for its obstructive sleep apnea (OSA) treatment devices increased 26% following 510(k) approval by the U.S. Food Drug and Administration (FDA) in November 2023.

During the fourth quarter of 2023, Vivos reported that new dentist inquiries increased 600% over the previous month and signed dentist enrollment contracts were up 38% sequentially compared to the third quarter following the clearance of its CARE oral medical devices.


 




Page 1 of 129
Next Page